ausblenden:
Schlagwörter:
CHL1, depression, gene expression, imipramine, ITGB3, lymphoblastoid cell line, MARS, mirtazapine, Munich Antidepressant Response Signature Project, paroxetine, response biomarker
Zusammenfassung:
Aim: The identification of antidepressant drugs (ADs) response
biomarkers in depression is of high clinical importance. We explored
CHL1 and ITGB3 expression as tentative response biomarkers. Materials &
methods: In vitro sensitivity to ADs, as well as gene expression and
genetic variants of the candidate genes CHL1, ITGB3 and SLC6A4 were
measured in lymphoblastoid cell lines (LCLs) of 58 depressed patients.
Results: An association between the clinical remission of depression and
the basal expression of CHL1 and ITGB3 was discovered. Individuals whose
LCLs expressed higher levels of CHL1 or ITGB3 showed a significantly
better remission upon AD treatment. In addition individuals with the
CHL1 rs1516338 TT genotype showed a significantly better remission after
5 weeks AD treatment than those carrying a CC genotype. No association
between the in vitro sensitivity of LCLs toward AD and the clinical
remission could be detected. Conclusion: CHL1 expression in
patient-derived LCLs correlated with the clinical outcome. Thus, it
could be a valid biomarker to predict the success of an antidepressant
therapy.
